Cargando…

Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT

Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) v...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera-Hidalgo, Laura, Luque-Márquez, Rafael, de Alarcon, Aristides, Guisado-Gil, Ana Belén, Gutierrez-Gutierrez, Belen, Navarro-Amuedo, Maria Dolores, Praena-Segovia, Julia, Carmona-Caballero, Juan Manuel, Fraile-Ramos, Elena, Gutierrez-Valencia, Alicia, Lopez-Cortes, Luis Eduardo, Gil-Navarro, Maria Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950875/
https://www.ncbi.nlm.nih.gov/pubmed/35329878
http://dx.doi.org/10.3390/jcm11061551
_version_ 1784675247863103488
author Herrera-Hidalgo, Laura
Luque-Márquez, Rafael
de Alarcon, Aristides
Guisado-Gil, Ana Belén
Gutierrez-Gutierrez, Belen
Navarro-Amuedo, Maria Dolores
Praena-Segovia, Julia
Carmona-Caballero, Juan Manuel
Fraile-Ramos, Elena
Gutierrez-Valencia, Alicia
Lopez-Cortes, Luis Eduardo
Gil-Navarro, Maria Victoria
author_facet Herrera-Hidalgo, Laura
Luque-Márquez, Rafael
de Alarcon, Aristides
Guisado-Gil, Ana Belén
Gutierrez-Gutierrez, Belen
Navarro-Amuedo, Maria Dolores
Praena-Segovia, Julia
Carmona-Caballero, Juan Manuel
Fraile-Ramos, Elena
Gutierrez-Valencia, Alicia
Lopez-Cortes, Luis Eduardo
Gil-Navarro, Maria Victoria
author_sort Herrera-Hidalgo, Laura
collection PubMed
description Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery.
format Online
Article
Text
id pubmed-8950875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89508752022-03-26 Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT Herrera-Hidalgo, Laura Luque-Márquez, Rafael de Alarcon, Aristides Guisado-Gil, Ana Belén Gutierrez-Gutierrez, Belen Navarro-Amuedo, Maria Dolores Praena-Segovia, Julia Carmona-Caballero, Juan Manuel Fraile-Ramos, Elena Gutierrez-Valencia, Alicia Lopez-Cortes, Luis Eduardo Gil-Navarro, Maria Victoria J Clin Med Article Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery. MDPI 2022-03-11 /pmc/articles/PMC8950875/ /pubmed/35329878 http://dx.doi.org/10.3390/jcm11061551 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Herrera-Hidalgo, Laura
Luque-Márquez, Rafael
de Alarcon, Aristides
Guisado-Gil, Ana Belén
Gutierrez-Gutierrez, Belen
Navarro-Amuedo, Maria Dolores
Praena-Segovia, Julia
Carmona-Caballero, Juan Manuel
Fraile-Ramos, Elena
Gutierrez-Valencia, Alicia
Lopez-Cortes, Luis Eduardo
Gil-Navarro, Maria Victoria
Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title_full Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title_fullStr Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title_full_unstemmed Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title_short Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
title_sort clinical outcomes of an innovative cefazolin delivery program for mssa infections in opat
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950875/
https://www.ncbi.nlm.nih.gov/pubmed/35329878
http://dx.doi.org/10.3390/jcm11061551
work_keys_str_mv AT herrerahidalgolaura clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT luquemarquezrafael clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT dealarconaristides clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT guisadogilanabelen clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT gutierrezgutierrezbelen clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT navarroamuedomariadolores clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT praenasegoviajulia clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT carmonacaballerojuanmanuel clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT fraileramoselena clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT gutierrezvalenciaalicia clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT lopezcortesluiseduardo clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat
AT gilnavarromariavictoria clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat